Referenzen

1. Dawber TR, Kannel WB. The Framingham study. An epidemiological approach to coronary heart disease. Circulation 1966; 34: 553-5.

2. Colditz GA, Stampfer MJ, Willett WC, Rosner B, Speizer FE, Hennekens CH. A prospective study of parental history of myocardial infarction and coronary heart disease in women. Am J Epidemiol 1986; 123: 48-58.

3. Schildkraut JM, Myers RH, Cupples LA, Kiely DK, Kannel WB. Coronary risk associated with age and sex of parental heart disease in the Framingham Study. Am J Cardiol 1989; 64: 555-9.

4. Scheuner MT. Genetic predisposition to coronary artery disease. Curr Opin Cardiol 2001; 16: 251-60.

5. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994; 330: 1041-6.

6. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.

7. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291: 1304-51.

8. Drysdale CM, McGraw DW, Stack CB, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 2000; 97: 10483-8.

9. Collins FS. Shattuck lecture--medical and societal consequences of the Human Genome Project. N Engl J Med 1999; 341: 28-37.

10. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996; 273: 1516-7.

11. Collins FS, Guyer MS, Charkravarti A. Variations on a theme: cataloging human DNA sequence variation. Science 1997; 278: 1580-1.

12. Sham PC, Cherny SS, Purcell S, Hewitt JK. Power of linkage versus association analysis of quantitative traits, by use of variance-components models, for sibship data. Am J Hum Genet 2000; 66: 1616-30.

13. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000; 405: 847-56.

14. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-4.

15. Sibani S, Christensen B, O'Ferrall E, et al. Characterization of six novel mutations in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with homocystinuria. Hum Mutat 2000; 15: 280-7.

16. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.

17. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6.

18. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-81.

19. Stehouwer CD, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJ, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vasc Biol 1998; 18: 1895-901.

20. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk 1998; 5: 229-32.

21. Brattstrom L, Wilcken DE. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000; 72: 315-23.

22. Voutilainen S, Rissanen TH, Virtanen J, Lakka TA, Salonen JT. Low dietary folate intake is associated with an excess incidence of acute coronary events: The Kuopio Ischemic Heart Disease Risk Factor Study. Circulation 2001; 103: 2674-80.

23. Voutilainen S, Lakka TA, Porkkala-Sarataho E, Rissanen T, Kaplan GA, Salonen JT. Low serum folate concentrations are associated with an excess incidence of acute coronary events: the Kuopio Ischaemic Heart Disease Risk Factor Study. Eur J Clin Nutr 2000; 54: 424-8.

24. Verhoef P, Stampfer MJ, Rimm EB. Folate and coronary heart disease. Curr Opin Lipidol 1998; 9: 17-22.

25. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998; 98: 204-10.

26. Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43: 414-21.

27. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.

[Seite 39↓]

28. Brattstrom L, Wilcken D, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease : the result of a meta-analysis. Circulation 1998; 98: 2520-6.

29. Harmon DL, Woodside JV, Yarnell JW, et al. The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. QJM 1996; 89: 571-7.

30. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.

31. Ma J, Stampfer MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996; 94: 2410-6.

32. Girelli D, Friso S, Trabetti E, et al. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood 1998; 91: 4158-63.

33. van der Put NM, Steegers Theunissen RP, Frosst P, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida [see comments]. Lancet 1995; 346: 1070-1.

34. Deloughery TG, Evans A, Sadeghi A, et al. Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease. Circulation 1996; 94: 3074-8.

35. Schwartz SM, Siscovick DS, Malinow MR, et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997; 96: 412-7.

36. Arruda VR, von Zuben PM, Chiaparini LC, Annichino Bizzacchi JM, Costa FF. The mutation Ala677-->Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost 1997; 77: 818-21.

37. Gallagher PM, Meleady R, Shields DC, et al. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation 1996; 94: 2154-8.

38. Kluijtmans LA, van den Heuvel LP, Boers GH, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.

39. Morita H, Kurihara H, Tsubaki S, et al. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler Thromb Vasc Biol 1998; 18: 1465-9.

40. Ou T, Yamakawa Kobayashi K, Arinami T, et al. Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: a case-control study. Atherosclerosis 1998; 137: 23-8.

41. Abbate R, Sardi I, Pepe G, et al. The high prevalence of thermolabile 5-10 methylenetetrahydrofolate reductase (MTHFR) in Italians is not associated to an increased risk for coronary artery disease (CAD). Thromb Haemost 1998; 79: 727-30.

42. Anderson JL, King GJ, Thomson MJ, et al. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol 1997; 30: 1206-11.

43. Brugada R, Marian AJ. A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. Atherosclerosis 1997; 128: 107-12.

44. Dunn J, Title LM, Bata I, et al. Relation of a common mutation in methylenetetrahydrofolate reductase to plasma homocysteine and early onset coronary artery disease. Clin Biochem 1998; 31: 95-100.

45. Verhoef P, Kok FJ, Kluijtmans LA, et al. The 677C-->T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis 1997; 132: 105-13.

46. Verhoef P, Rimm EB, Hunter DJ, et al. A common mutation in the methylenetetrahydrofolate reductase gene and risk of coronary heart disease: results among U.S. men. J Am Coll Cardiol 1998; 32: 353-9.

47. van Bockxmeer FM, Mamotte CD, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation 1997; 95: 21-3.

48. Gardemann A, Weidemann H, Philipp M, et al. The TT genotype of the methylenetetrahydrofolate reductase C677T gene polymorphism is associated with the extent of coronary atherosclerosis in patients at hight risk for coronary artery disease. Eur Heart J 1999; 20: 584-592.

49. Adams M, Smith PD, Martin D, Thompson JR, Lodwick D, Samani NJ. Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction. QJM 1996; 89: 437-44.

50. Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. A case-control study. Circulation 1996; 94: 1812-4.

[Seite 40↓]

51. Thuillier L, Chadefaux-Vekemans B, Bonnefont JP, et al. Does the polymorphism 677C-T of the 5,10-methylenetetrahydrofolate reductase gene contribute to homocysteine-related vascular disease. J Inher Metab dis 1998; 21: 812-822.

52. van der Put NM, Gabreels F, Stevens EM, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998; 62: 1044-51.

53. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64: 169-72.

54. Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993; 71: 337-59.

55. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-50.

56. Harpel PC, Zhang X, Borth W. Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis. J Nutr 1996; 126: 1285S-9S.

57. Zhang X, Li H, Jin H, Ebin Z, Brodsky S, Goligorsky MS. Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol 2000; 279: F671-8.

58. Upchurch GR, Jr., Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272: 17012-7.

59. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; 2: 1057-8.

60. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-7.

61. Murrell GA, Jang D, Williams RJ. Nitric oxide activates metalloprotease enzymes in articular cartilage. Biochem Biophys Res Commun 1995; 206: 15-21.

62. von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci U S A 1995; 92: 1137-41.

63. Kelly RA, Balligand JL, Smith TW. Nitric oxide and cardiac function. Circ Res 1996; 79: 363-80.

64. Cooke JP, Dzau VJ. Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases. Circulation 1997; 96: 379-82.

65. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med 1996; 2: 41-5.

66. Stangl K, Cascorbi I, Laule M, et al. High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease. Pharmacogenetics 2000; 10: 133-40.

67. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-26.

68. Fredrickson BJ, Dong JF, McIntire LV, Lopez JA. Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Blood 1998; 92: 3684-93.

69. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84: 289-97.

70. Furihata K, Nugent DJ, Kunicki TJ. Influence of platelet collagen receptor polymorphisms on risk for arterial thrombosis. Arch Pathol Lab Med 2002; 126: 305-9.

71. Reiner AP, Siscovick DS, Rosendaal FR. Platelet glycoprotein gene polymorphisms and risk of thrombosis: facts and fancies. Rev Clin Exp Hematol 2001; 5: 262-87; discussion 311-2.

72. Lopez JA, Dong JF. Structure and function of the glycoprotein Ib-IX-V complex. Curr Opin Hematol 1997; 4: 323-9.

73. Ware J. Molecular analyses of the platelet glycoprotein Ib-IX-V receptor. Thromb Haemost 1998; 79: 466-78.

74. Miller JL. Platelet-type von Willebrand disease. Thromb Haemost 1996; 75: 865-9.

75. Lopez JA, Andrews RK, Afshar Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood 1998; 91: 4397-418.

76. Moroi M, Jung SM, Yoshida N. Genetic polymorphism of platelet glycoprotein Ib. Blood 1984; 64: 622-9.

77. Ishida F, Furihata K, Ishida K, et al. The largest variant of platelet glycoprotein Ib alpha has four tandem repeats of 13 amino acids in the macroglycopeptide region and a genetic linkage with methionine145. Blood 1995; 86: 1357-60.

78. Lopez JA, Ludwig EH, McCarthy BJ. Polymorphism of human glycoprotein Ib alpha results from a variable number of tandem repeats of a 13-amino acid sequence in the mucin-like macroglycopeptide region. Structure/function implications. J Biol Chem 1992; 267: 10055-61.

[Seite 41↓]

79. Kuijpers RW, Faber NM, Cuypers HT, Ouwehand WH, von dem Borne AE. NH2-terminal globular domain of human platelet glycoprotein Ib alpha has a methionine 145/threonine145 amino acid polymorphism, which is associated with the HPA-2 (Ko) alloantigens. J Clin Invest 1992; 89: 381-4.

80. Kuijpers RW, Ouwehand WH, Bleeker PM, Christie D, von dem Borne AE. Localization of the platelet-specific HPA-2 (Ko) alloantigens on the N-terminal globular fragment of platelet glycoprotein Ib alpha. Blood 1992; 79: 283-8.

81. Murata M, Furihata K, Ishida F, Russell SR, Ware J, Ruggeri ZM. Genetic and structural characterization of an amino acid dimorphism in glycoprotein Ib alpha involved in platelet transfusion refractoriness. Blood 1992; 79: 3086-90.

82. Kozak M. Possible role of flanking nucleotides in recognition of the AUG initiator codon by eukaryotic ribosomes. Nucleic Acids Res 1981; 9: 5233-62.

83. Afshar Kharghan V, Li CQ, Khoshnevis Asl M, Lopez JA. Kozak sequence polymorphism of the glycoprotein (GP) Ibalpha gene is a major determinant of the plasma membrane levels of the platelet GP Ib-IX-V complex. Blood 1999; 94: 186-91.

84. Santoso S, Zimmermann P, Sachs UJ, Gardemann A. The impact of the Kozak sequence polymorphism of the glycoprotein Ib alpha gene on the risk and extent of coronary heart disease. Thromb Haemost 2002; 87: 345-6.

85. Ishida F, Ito T, Takei M, Shimodaira S, Kitano K, Kiyosawa K. Genetic linkage of Kozak sequence polymorphism of the platelet glycoprotein Ib alpha with human platelet antigen-2 and variable number of tandem repeats polymorphism, and its relationship with coronary artery disease. Br J Haematol 2000; 111: 1247-9.

86. Corral J, Lozano ML, Gonzalez-Conejero R, et al. A common polymorphism flanking the ATG initiator codon of GPIb alpha does not affect expression and is not a major risk factor for arterial thrombosis. Thromb Haemost 2000; 83: 23-8.

87. Ito T, Ishida F, Shimodaira S, Kitano K. Polymorphisms of platelet membrane glycoprotein Ib alpha and plasma von Willebrand factor antigen in coronary artery disease. Int J Hematol 1999; 70: 47-51.

88. Murata M, Matsubara Y, Kawano K, et al. Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation. Circulation 1997; 96: 3281-6.

89. Douglas H, Michaelides K, Gorog DA, et al. Platelet membrane glycoprotein Ibalpha gene -5T/C Kozak sequence polymorphism as an independent risk factor for the occurrence of coronary thrombosis. Heart 2002; 87: 70-4.

90. Mikkelsson J, Perola M, Penttila A, Karhunen PJ. Platelet glycoprotein Ibalpha HPA-2 Met/VNTR B haplotype as a genetic predictor of myocardial infarction and sudden cardiac death. Circulation 2001; 104: 876-80.

91. Gonzalez Conejero R, Lozano ML, Rivera J, et al. Polymorphisms of platelet membrane glycoprotein Ib associated with arterial thrombotic disease. Blood 1998; 92: 2771-6.

92. Mercier B, Munier S, Bertault V, Mansourati J, Blanc JJ, Ferec C. Myocardial infarction: absence of association with VNTR polymorphism of GP Ibalpha. Thromb Haemost 2000; 84: 921-2.

93. Santoro SA. Platelet surface collagen receptor polymorphisms: variable receptor expression and thrombotic/hemorrhagic risk. Blood 1999; 93: 3575-7.

94. Kunicki TJ, Orchekowski R, Annis D, Honda Y. Variability of integrin alpha 2 beta 1 activity on human platelets. Blood 1993; 82: 2693-703.

95. Kritzik M, Savage B, Nugent DJ, Santoso S, Ruggeri ZM, Kunicki TJ. Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2 beta1 density. Blood 1998; 92: 2382-8.

96. Nieuwenhuis HK, Akkerman JW, Houdijk WP, Sixma JJ. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature 1985; 318: 470-2.

97. Nieuwenhuis HK, Sakariassen KS, Houdijk WP, Nievelstein PF, Sixma JJ. Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading. Blood 1986; 68: 692-5.

98. Kunicki TJ, Annis DS, Felding Habermann B. Molecular determinants of arg-gly-asp ligand specificity for beta3 integrins. J Biol Chem 1997; 272: 4103-7.

99. Jacquelin B, Tarantino MD, Kritzik M, et al. Allele-dependent transcriptional regulation of the human integrin alpha2 gene. Blood 2001; 97: 1721-6.

100. Di Paola J, Federici AB, Mannucci PM, et al. Low platelet alpha2beta1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system. Blood 1999; 93: 3578-82.

101. Roest M, Banga JD, Grobbee DE, et al. Homozygosity for 807 T polymorphism in alpha(2) subunit of platelet alpha(2)beta(1) is associated with increased risk of cardiovascular mortality in high-risk women. Circulation 2000; 102: 1645-50.

102. Carlsson LE, Santoso S, Spitzer C, Kessler C, Greinacher A. The alpha2 gene coding sequence T807/A873 of the platelet collagen receptor integrin alpha2beta1 might be a genetic risk factor for the development of stroke in younger patients. Blood 1999; 93: 3583-6.

[Seite 42↓]

103. Reiner AP, Kumar PN, Schwartz SM, et al. Genetic variants of platelet glycoprotein receptors and risk of stroke in young women. Stroke 2000; 31: 1628-33.

104. Casorelli I, De Stefano V, Leone AM, et al. The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population. Br J Haematol 2001; 114: 150-4.

105. Moshfegh K, Wuillemin WA, Redondo M, et al. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet 1999; 353: 351-4.

106. Morita H, Kurihara H, Imai Y, et al. Lack of association between the platelet glycoprotein Ia C807T gene polymorphism and myocardial infarction in Japanese. An approach entailing melting curve analysis with specific fluorescent hybridization probes. Thromb Haemost 2001; 85: 226-30.

107. Benze G, Heinrich J, Schulte H, et al. Association of the GPIa C807T and GPIIIa PlA1/A2 polymorphisms with premature myocardial infarction in men. Eur Heart J 2002; 23: 325-30.

108. Santoso S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann A. Association of the Platelet Glycoprotein Ia C807T Gene Polymorphism With Nonfatal Myocardial Infarction in Young Patients. Blood 1999; 93: 2449-2453.

109. Croft SA, Hampton KK, Sorrell JA, et al. The GPIa C807T dimorphism associated with platelet collagen receptor density is not a risk factor for myocardial infarction. Br J Haematol 1999; 106: 771-6.

110. Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53: 505-18.

111. Rapaport SI, Rao LV. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 1992; 12: 1111-21.

112. Nemerson Y. Tissue factor: then and now. Thromb Haemost 1995; 74: 180-4.

113. Rao LV, Rapaport SI. Cells and the activation of factor VII. Haemostasis 1996; 26: 1-5.

114. Muller YA, Ultsch MH, Kelley RF, de Vos AM. Structure of the extracellular domain of human tissue factor: location of the factor VIIa binding site. Biochemistry 1994; 33: 10864-70.

115. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.

116. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95: 1517-32.

117. Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 1991; 11: 540-6.

118. Bernardi F, Marchetti G, Pinotti M, et al. Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. Arterioscler Thromb Vasc Biol 1996; 16: 72-6.

119. Pollak ES, Hung HL, Godin W, Overton GC, High KA. Functional characterization of the human factor VII 5'-flanking region. J Biol Chem 1996; 271: 1738-47.

120. Lane A, Cruickshank JK, Mitchell J, Henderson A, Humphries S, Green F. Genetic and environmental determinants of factor VII coagulant activity in ethnic groups at differing risk of coronary heart disease. Atherosclerosis 1992; 94: 43-50.

121. Iacoviello L, Di Castelnuovo A, De Knijff P, et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction [see comments]. N Engl J Med 1998; 338: 79-85.

122. Ghaddar HM, Folsom AR, Aleksic N, et al. Correlation of factor VIIa values with factor VII gene polymorphism, fasting and postprandial triglyceride levels, and subclinical carotid atherosclerosis. Circulation 1998; 98: 2815-21.

123. Hunault M, Arbini AA, Lopaciuk S, Carew JA, Bauer KA. The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies. Arterioscler Thromb Vasc Biol 1997; 17: 2825-9.

124. Doggen CJ, Manger Cats V, Bertina RM, Reitsma PH, Vandenbroucke JP, Rosendaal FR. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. Thromb Haemost 1998; 80: 281-5.

125. Heywood DM, Ossei-Gerning N, Grant PJ. Association of factor VII: C levels with environmental and genetic factors in patients with ischaemic heart disease and coronary atheroma characterised by angiography. Thromb Haemost 1996; 76: 161-5.

126. Lane A, Green F, Scarabin PY, et al. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. Atherosclerosis 1996; 119: 119-27.

127. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 1979; 59: 607-9.

128. Kluijtmans LA, Kastelein JJ, Lindemans J, et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1997; 96: 2573-7.

[Seite 43↓]

129. Blom HJ, Verhoef DP. Hyperhomocysteinemia, MTHFR, and risk of vascular disease. Circulation 2000; 101: E171; author reply E173.

130. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. Jama 2002; 288: 2015-22.

131. Malinow MR, Nieto FJ, Kruger WD, et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol 1997; 17: 1157-62.

132. Ma J, Stampfer MJ, Giovannucci E, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997; 57: 1098-102.

133. Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. Jama 1998; 279: 359-64.

134. Tucker KL, Selhub J, Wilson PW, Rosenberg IH. Dietary intake pattern relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. J Nutr 1996; 126: 3025-31.

135. Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 2001; 73: 613-21.

136. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. Jama 1997; 277: 1775-81.

137. Amorim Cruz JA, Moreiras O, Brzozowska A. Longitudinal changes in the intake of vitamins and minerals of elderly Europeans. SENECA Investigators. Eur J Clin Nutr 1996; 50: S77-85.

138. Clarke R, Collins R. Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk 1998; 5: 249-55.

139. Hui J, Stangl K, Lane WS, Bindereif A. HnRNP L stimulates splicing of the eNOS gene by binding to variable-length CA repeats. Nat Struct Biol 2003; 10: 33-7.

140. Verhoef P. Hyperhomocysteinemia and risk of vascular disease in women. Semin Thromb Hemost 2000; 26: 325-34.

141. Yeghiazarians Y, Braunstein JA, Askari A, Stone P. Medical Progress: Unstable Angina Pectoris. N Engl J Med 2000; 342: 101-114.

142. Romo GM, Dong JF, Schade AJ, et al. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J Exp Med 1999; 190: 803-14.

143. Simon DI, Chen Z, Xu H, et al. Platelet Glycoprotein Ibalpha Is a Counterreceptor for the Leukocyte Integrin Mac-1 (CD11b/CD18). J Exp Med 2000; 192: 193-204.

144. von Beckerath N, Koch W, Mehilli J, et al. Glycoprotein Ia C807T polymorphism and risk of restenosis following coronary stenting. Atherosclerosis 2001; 156: 463-8.

145. Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence. Blood 1997; 89: 1939-43.

146. Corral J, Rivera J, Gonzalez-Conejero R, Vicente V. The number of platelet glycoprotein Ia molecules is associated with the genetically linked 807 C/T and HPA-5 polymorphisms. Transfusion 1999; 39: 372-8.

147. von Beckerath N, Koch W, Mehilli J, Böttiger C, Schömig A, Kastrati A. Glycoprotein Ia gene C807T polymorphism and risk for major adverse cardiac events within the first 30 days after coronary artery stenting. Blood 2000; 95: 3297-3301.

148. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-9.

149. Fuster V. Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994; 90: 2126-46.

150. Gutensohn K, Beythien C, Bau J, Meinertz T, Kuehnl P. Flow cytometric analysis of coronary stent-induced alterations of platelet antigens in an in vitro model. Thromb Res 1997; 86: 49-56.

151. Feng D, Tofler GH, Larson MG, et al. Factor VII gene polymorphism, factor VII levels, and prevalent cardiovascular disease: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2000; 20: 593-600.

152. Golino P, Ragni M, Cirillo P, et al. Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis. Circ Res 1998; 82: 39-46.

153. Nurnberg B, Gudermann T, Schultz G. Receptors and G proteins as primary components of transmembrane signal transduction. Part 2. G proteins: structure and function. J Mol Med 1995; 73: 123-32.

154. Levine MA, Smallwood PM, Moen PT, Jr., Helman LJ, Ahn TG. Molecular cloning of beta 3 subunit, a third form of the G protein beta-subunit polypeptide. Proc Natl Acad Sci U S A 1990; 87: 2329-33.

155. Ansari-Lari MA, Muzny DM, Lu J, et al. A gene-rich cluster between the CD4 and triosephosphate isomerase genes at human chromosome 12p13. Genome Res 1996; 6: 314-26.

156. Koch WJ, Hawes BE, Allen LF, Lefkowitz RJ. Direct evidence that Gi-coupled receptor stimulation of mitogen-activated protein kinase is mediated by G beta gamma activation of p21ras. Proc Natl Acad Sci U S A 1994; 91: 12706-10.

[Seite 44↓]

157. Davies MG, Huynh TT, Fulton GJ, et al. G protein signaling and vein graft intimal hyperplasia: reduction of intimal hyperplasia in vein grafts by a Gbetagamma inhibitor suggests a major role of G protein signaling in lesion development. Arterioscler Thromb Vasc Biol 1998; 18: 1275-80.

158. Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci U S A 1998; 95: 8070-4.

159. Siffert W, Rosskopf D, Siffert G, et al. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 1998; 18: 45-8.

160. Baumgart D, Naber C, Haude M, et al. G protein beta3 subunit 825T allele and enhanced coronary vasoconstriction on alpha(2)-adrenoceptor activation. Circ Res 1999; 85: 965-9.

161. Virchow S, Ansorge N, Rosskopf D, Rubben H, Siffert W. The G protein beta3 subunit splice variant Gbeta3-s causes enhanced chemotaxis of human neutrophils in response to interleukin-8. Naunyn Schmiedebergs Arch Pharmacol 1999; 360: 27-32.

162. Virchow S, Ansorge N, Rubben H, Siffert G, Siffert W. Enhanced fMLP-stimulated chemotaxis in human neutrophils from individuals carrying the G protein beta3 subunit 825 T-allele. FEBS Lett 1998; 436: 155-8.

163. Wenzel RR, Siffert W, Bruck H, Philipp T, Schäfers RF. Enhanced vasoconstriction to endothelin-1, angiotensin II and noradrenaline in carriers of the GNB3 825T allele in the skin microcirculation. Pharmacogenetics 2002; 12: 489-95.

164. Benjafield AV, Jeyasingam CL, Nyholt DR, Griffiths LR, Morris BJ. G-protein beta3 subunit gene (GNB3) variant in causation of essential hypertension. Hypertension 1998; 32: 1094-7.

165. Schunkert H, Hense HW, Doring A, Riegger GA, Siffert W. Association between a polymorphism in the G protein beta3 subunit gene and lower renin and elevated diastolic blood pressure levels. Hypertension 1998; 32: 510-3.

166. Beige J, Hohenbleicher H, Distler A, Sharma AM. G-protein beta3 subunit C825T variant and ambulatory blood pressure in essential hypertension. Hypertension 1999; 33: 1049-1051.

167. Brand E, Herrmann SM, Nicaud V, et al. The 825C/T polymorphism of the G-protein subunit beta3 is not related to hypertension. Hypertension 1999; 33: 1175-8.

168. Turner ST, Schwart GL, Chapman AB, Boerwinkle E. C825T polymorphism of the G protein beta3-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001; 37: 739-743.

169. von Beckerath N, Kastrati A, Koch W, et al. G protein beta3 subunit polymorphism and risk of thrombosis and restenosis following coronary stent placement. Atherosclerosis 2000; 149: 151-5.

170. Hildebrandt JD. Role of subunit diversity in signaling by heterotrimeric G proteins. Biochem Pharmacol 1997; 54: 325-39.

171. Tomaszewski M, Charchar FJ, Padmanabhan S, Zukowska-Szczechowska E, Grzeszczak W, Dominiczak AF. Cardiovascular diseases and G-protein beta3 subunit gene (GNB3) in the era of genomewide scans. J Hum Hypertens 2003; 17: 379-380.

172. Castellano M. Genetic association studies on gender- and age-related phenotypes: the case of GNB3 gene. J Hypertens 2003; 21: 683-685.

173. Brand E, Wang J-G, Herrmann SM, Staessen JA. An epidemiological study of blood pressure and metabolic phenotypes in relation to the Gbeta3 C825T polymorphism. J Hypertens 2003; 21: 729-737.

174. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001; 29: 306-9.

175. Freely associating. Nat Genet 1999; 22: 1-2.

176. Tabor HK, Risch NJ, Myers RM. Opinion: Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genet 2002; 3: 391-7.

177. Hegele RA. SNP Judgments and Freedom of Association. Arterioscler Thromb Vasc Biol 2002; 22: 1058-1061.

178. Freimer N, Sabatti C. The Human Phenome Project. Nat Genet 2003; 34: 15-21.

179. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999; 65: 220-8.

180. Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002; 347: 1135-42.

181. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies support a contribution of common variants to susceptibility to common disease. Nat Genet 2003; 33: 177-182.

182. Tiret L, Poirier O, Nicaud V, et al. Heterogeneity of linkage disequilibrium in human genes has implications for association studies of common diseases. Hum Mol Genet 2002; 11: 419-429.

183. Cambien F, Poirier O, Nicaud V, et al. Sequence Diversity in 36 Candidate Genes for Cardiovascular Disorders. Am J Hum Genet 1999; 65: 183-191.

184. Cargill M, Altshuler D, Ireland J, et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 1999; 22: 231-8.

[Seite 45↓]

185. Halushka MK, Fan JB, Bentley K, et al. Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet 1999; 22: 239-47.

186. Klerkx AH, Tanck MW, Kastelein JJ, et al. Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C-->A polymorphism and a novel promoter variant are independently associated with CETP concentration. Hum Mol Genet 2003; 12: 111-23.

187. Zhang K, Calabrese P, Nordborg M, Sun F. Haplotype block structure and its applications to association studies: power and study designs. Am J Hum Genet 2002; 71: 1386-94.

188. Stephens JC, Schneider JA, Tanguay DA, et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science 2001; 293: 489-93.

189. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225-9.

190. Patil N, Berno AJ, Hinds DA, et al. Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science 2001; 294: 1719-23.

191. Goddard KA, Hopkins PJ, Hall JM, Witte JS. Linkage disequilibrium and allele-frequency distributions for 114 single-nucleotide polymorphisms in five populations. Am J Hum Genet 2000; 66: 216-34.

192. Ardlie KG, Kruglyak L, Seielstad M. Patterns of linkage disequilibrium in the human genome. Nat Rev Genet 2002; 3: 299-309.

193. Wang N, Akey JM, Zhang K, Chakraborty R, Jin L. Distribution of recombination crossovers and the origin of haplotype blocks: the interplay of population history, recombination, and mutation. Am J Hum Genet 2002; 71: 1227-34.

194. Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES. High-resolution haplotype structure in the human genome. Nat Genet 2001; 29: 229-32.

195. Dawson E, Abecasis GR, Bumpstead S, et al. A first-generation linkage disequilibrium map of human chromosome 22. Nature 2002; 418: 544-8.

196. Johnson GC, Esposito L, Barratt BJ, et al. Haplotype tagging for the identification of common disease genes. Nat Genet 2001; 29: 233-7.

197. Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001; 409: 928-33.

198. Couzin J. Genomics. New mapping project splits the community. Science 2002; 296: 1391-1393.

199. Cardon LR, Abecasis GR. Using haplotype blocks to map human complex trait loci. Trends Genet 2003; 19: 135-40.